Concepedia

Andrew Protheroe

AP

Statistics

Publications

90

Citations

14.2K

H-Index

47

Active since

1999

Affiliations

Churchill Hospital(Current)

University of Oxford

University College London

Oxford University Hospitals NHS Trust

Institute of Cancer Research

Andrew Protheroe is an author at Churchill Hospital specializing in medicine, oncology, and pharmacology.

ORCID

Publications per year

1999–2024

90

Publications

90

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

Karim Fizazi, NamPhuong Tran, Luis Fein et al. · New England Journal of Medicine · 2017 · 2.2K citations · Full text

, , +15

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

Joaquı́n Mateo, Suzanne Carreira, Shahneen Sandhu et al. · New England Journal of Medicine · 2015 · 2.2K citations · Full text

, , +17

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

Nicholas D. James, Johann S. de Bono, Melissa Spears et al. · New England Journal of Medicine · 2017 · 1.8K citations · Full text

, , +14

Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial

Karim Fizazi, NamPhuong Tran, Luis Fein et al. · The Lancet Oncology · 2019 · 813 citations · Full text

, , +16

The safety and feasibility of extracorporeal high-intensity focused ultrasound (HIFU) for the treatment of liver and kidney tumours in a Western population

Rowland Illing, James E. Kennedy, Feng Wu et al. · British Journal of Cancer · 2005 · 581 citations · Full text

, , +16

1–5 of 90